Terlipressin infusion in Living Donor Liver Transplantation

Impact of intra and postoperative terlipressin infusion in patients undergoing Living Donor Liver Transplantation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201402000752252

Enrollment

Registered

2014-01-28

Start date

2013-08-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive System Surgery End-stage liver disease going for liver transplantation

Interventions

Terlipressin

Control

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Model for end stage liver disease (MELD) between 12 and 20.

Exclusion criteria

Exclusion criteria: Systemic vascular resistance index (SVRI) ¿ 1700 dyne·s/cm5/m2 History of myocardial infarction. Evidence of cardiac decompensation. Severe haemodynamic instability. Primary renal dysfunction.

Design outcomes

Primary

Measure	Time frame
renal fuction	—

Secondary

Measure	Time frame
catacholamine support;systemic vascular resistance	—

Countries

Egypt

Contacts

Public ContactElsayedamr Basma

Patient information Manager

elsayedamr@yahoo.com002-01223106023

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026